source
- Verastem makes its stand as a RevMed competitor in pancreatic cancerVerastem Oncology had a big Wednesday morning: It announced new data amid a tense competition for the next-wave KRAS agents, as well as a $250 million raise and the departure of its CEO. The Massac…
- Convenience Kit Recall: AVID Medical Removes Convenience Kits Affected by BD ChloraPrep Applicator RecallAvid Medical is removing certain convenience kits affected by the BD ChloraPrep Applicator Recall that may be contaminated with Aspergillus penicillioides.fda medwatch · 6d ago↗ source
- Gilead signs $1.9 billion deal with Vir Biotechnology to license dual-masked T-cell engagers for oncology